Mode
Text Size
Log in / Sign up
Phase 2 N=41 Randomized Quadruple-blind Treatment

A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale

Osteoarthritis, Knee

Enrolled (actual)
41
Serious AEs
0.0%
Results posted
Jun 2020
Primary outcome: Primary: Sum of Change in Brief Arthritis Stiffness Scale (BASS) Scores Over the 4-day Treatment Period — -12.6; -13.6; -11.7; -2.3 Scores on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Naproxen Sodium (Aleve, BAY117031) (Drug); Acetaminophen ER (Drug); Celecoxib (Drug); Placebo (Drug)
Age
Adult, Older Adult · 40+ yrs
Sex
All
Sponsor
Bayer
Primary completion
Jun 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Sum of Change in Brief Arthritis Stiffness Scale (BASS) Scores Over the 4-day Treatment Period
-12.6; -13.6; -11.7; -2.3
SECONDARY
Absolute Brief Arthritis Stiffness Scale (BASS) Score at Each Time Point
23.0; 23.3; 24.6; 22.6; 20.8; 19.7
SECONDARY
Change From Baseline in Brief Arthritis Stiffness Scale (BASS) Score at Day 4
-5.2; -5.3; -4.8; -1.3

Summary

Osteoarthritis is a common, chronic, progressive, skeletal, degenerative disorder that frequently affects several joints such as knee, hip, spine and hands.This placebo-controlled clinical trial assessed the effects of naproxen sodium, acetaminophen and celecoxib on stiffness in subjects with osteoarthritis.

Eligibility Criteria

Inclusion Criteria

  • Age between 40 and 80 years
  • Body Mass Index (BMI) between 18 and <40 kg/m^2
  • Unilateral or bilateral osteoarthritis of the knee
  • Diagnostic quality radiography of the target knee performed no more than 1 year prior to baseline showing evidence of osteoarthritis (OA) with Kellgren and Lawrence grade of II or III
  • Joint Stiffness Severity score ≥3.0 on a 0-10 numerical rating scale (NRS) at screening

Exclusion Criteria

  • History of underlying inflammatory arthropathy, rheumatoid arthritis or fibromyalgia
  • History of or scheduled for target knee replacement surgery
  • Recent injury in target knee (past 4 months)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03570554). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search